Oxaliplatin (OX) after irinotecan (IRI): antitumour activity and clinical benefit of 3rd and higher line chemotherapy with ox for patients (pts) with metastatic colorectal cancer (MCC) after failure of IRI

Albrecht Kretzschmar(Roche (Switzerland)), Peter Reichardt(Helios Hospital Berlin-Buch), Jochen Metzger, Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Martin Wilhelm(Nuremberg Hospital), C Kaufmann, H. Kröning(Praxis für Hämatologie und Onkologie), Helmut Schumacher(Cooper University Hospital)

European Journal of Cancer

September 1, 1999

10.1016/s0959-8049(99)80696-0

Cited by 4

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|751

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

|European Journal of Cancer|2019|724